PE 22-28

PE-22-28, also known as Spadin or TREK-1 blocker, is a cognitive classification research peptide that has garnered attention in neuroscience research for its unique mechanism of action. This compound operates by selectively blocking TREK-1 potassium channels, which play crucial roles in regulating neuronal excitability and mood-related pathways. The mechanism of PE-22-28 centres on its inhibition of TREK-1 potassium channels, leading to enhanced neurotransmitter release, particularly serotonin. This action contributes to the compound's observed rapid antidepressant effects in research models. Additionally, the modulation of synaptic plasticity through this pathway suggests potential cognitive-enhancing properties. Primary research effects observed in laboratory studies include rapid antidepressant effects, improved cognitive function, enhanced mood stabilisation, increased synaptic plasticity, and potential anxiolytic effects. These findings have positioned PE-22-28 as a compound of significant interest in neuropsychiatric research. The current evidence grade for PE-22-28 is classified as C, indicating that whilst promising effects have been observed, the research base requires expansion. Existing evidence derives primarily from animal studies, which demonstrate the compound's rapid antidepressant and cognitive-enhancing properties. However, no published human clinical trials are currently available, highlighting the need for further research to confirm efficacy and safety profiles in human models. Researchers investigating PE-22-28 should note that this peptide represents an emerging area of neuroscience research, with its TREK-1 channel blocking mechanism offering a novel approach to studying mood regulation and cognitive enhancement pathways.